Arterielle Hypertonie – Therapie

Ulrich Kintscher

doi:10.1055/a-1367-4023

Kardiologie up2date, Table of Contents

Kardiologie up2date 2022; 18(03): 233-248
DOI: 10.1055/a-1367-4023

Koronare Herzkrankheit (KHK)

Arterielle Hypertonie – Therapie

Authors

Ulrich Kintscher

Abstract

All articles of this category

Ein erhöhter systolischer Blutdruck ist weltweit immer noch der bedeutendste Risikofaktor für Tod. Trotz verbesserter Versorgung der Patienten*innen mit arterieller Hypertonie ist der Blutdruck vieler Hypertoniker*innen nicht kontrolliert. Eine moderne antihypertensive Therapie basiert auf Lebensstilveränderungen und einer frühen pharmakologischen Kombinationstherapie. In diesem Beitrag werden aktuelle Therapieverfahren zur Behandlung der arteriellen Hypertonie besprochen.

Schlüsselwörter

arterielle Hypertonie - antihypertensive Therapie - Blutdruckkontrolle - pharmakologische Therapie - Zielblutdruckwert

Full Text

References

Literatur
1 GBD 2019 Risk Factors Collaborators. Global burden of 87 risk factors in 204 countries and territories, 1990–2019: a systematic analysis for the Global Burden of Disease Study 2019. Lancet 2020; 396: 1223-1249
2 NCD Risk Factors Collaboration (NCD-RisC). Worldwide trends in hypertension prevalence and progress in treatment and control from 1990 to 2019: a pooled analysis of 1201 population-representative studies with 104 million participants. Lancet 2021; 398: 957-980
3 Williams B, Mancia G, Spiering W. et al. 2018 ESC/ESH Guidelines for the management of arterial hypertension. Eur Heart J 2018; 39: 3021-3104
4 Neal B, Wu Y, Feng X. et al. Effect of Salt Substitution on Cardiovascular Events and Death. N Engl J Med 2021; 385: 1067-1077
5 Bakris G, Sarafidis P, Agarwal R. et al. Review of blood pressure control rates and outcomes. J Am Soc Hypertens 2014; 8: 127-141
6 Persu A, Lopez-Sublet M, Algharably EAE. et al. Starting Antihypertensive Drug Treatment With Combination Therapy: Controversies in Hypertension – Pro Side of the Argument. Hypertension 2021; 77: 800-805
7 Weber MA, Julius S, Kjeldsen SE. et al. Blood pressure dependent and independent effects of antihypertensive treatment on clinical events in the VALUE Trial. Lancet 2004; 363: 2049-2051
8 Kintscher U. Update Hypertonie: Ab wann und wie behandeln?. CME 2020; 17: 9-17
9 Naderi SH, Bestwick JP, Wald DS. Adherence to drugs that prevent cardiovascular disease: meta-analysis on 376,162 patients. Am J Med 2012; 125: 882-887.e1
10 Gupta P, Patel P, Strauch B. et al. Risk Factors for Nonadherence to Antihypertensive Treatment. Hypertension 2017; 69: 1113-1120
11 Gupta AK, Arshad S, Poulter NR. Compliance, safety, and effectiveness of fixed-dose combinations of antihypertensive agents: a meta-analysis. Hypertension 2010; 55: 399-407
12 Rea F, Corrao G, Merlino L. et al. Early cardiovascular protection by initial two-drug fixed-dose combination treatment vs. monotherapy in hypertension. Eur Heart J 2018; 39: 3654-3661
13 Williams B, MacDonald TM, Morant S. et al. Spironolactone versus placebo, bisoprolol, and doxazosin to determine the optimal treatment for drug-resistant hypertension (PATHWAY-2): a randomised, double-blind, crossover trial. Lancet 2015; 386: 2059-2068
14 Mahfoud F, Böhm M, Dörr O. et al. Arterielle Hypertonie – Was war 2020 wichtig?. Kardiologe 2021; 15: 127-132
15 Vaduganathan M, Vardeny O, Michel T. et al. Renin-Angiotensin-Aldosterone System Inhibitors in Patients with Covid-19. N Engl J Med 2020; 382: 1653-1659
16 Mancia G, Rea F, Ludergnani M. et al. Renin-Angiotensin-Aldosterone System Blockers and the Risk of Covid-19. N Engl J Med 2020; 382: 2431-2440
17 Reynolds HR, Adhikari S, Pulgarin C. et al. Renin-Angiotensin-Aldosterone System Inhibitors and Risk of Covid-19. N Engl J Med 2020; 382: 2441-2448
18 Semenzato L, Botton J, Drouin J. et al. Antihypertensive Drugs and COVID-19 Risk: A Cohort Study of 2 Million Hypertensive Patients. Hypertension 2021; 77: 833-842
19 Cohen JB, Hanff TC, William P. et al. Continuation versus discontinuation of renin-angiotensin system inhibitors in patients admitted to hospital with COVID-19: a prospective, randomised, open-label trial. Lancet Respir Med 2021; 9: 275-284
20 Lopes RD, Macedo AVS, de Barros E Silva PGM. et al. Effect of Discontinuing vs Continuing Angiotensin-Converting Enzyme Inhibitors and Angiotensin II Receptor Blockers on Days Alive and Out of the Hospital in Patients Admitted With COVID-19: A Randomized Clinical Trial. JAMA 2021; 325: 254-264
21 Savoia C, Volpe M, Kreutz R. Hypertension, a Moving Target in COVID-19: Current Views and Perspectives. Circ Res 2021; 128: 1062-1079
22 Schmieder RE, Mahfoud F, Mancia G. et al. European Society of Hypertension position paper on renal denervation 2021. J Hypertens 2021; 39: 1733-1741
23 Mahfoud F, Galle J, Schunkert H. et al. Kriterien der Deutschen Gesellschaft für Kardiologie – Herz- und Kreislaufforschung e. V. (DGK), der Deutschen Hochdruckliga e. V. DHL®/Deutschen Gesellschaft für Hypertonie und Prävention und der Deutschen Gesellschaft für Nephrologie (DGfN) zur Zertifizierung von „Renale-Denervations-Zentren (RDZ)“ – Update. Kardiologe 2021; 15: 463-470
24 Cockburn J, Moar VA, Ounsted M. et al. Final report of study on hypertension during pregnancy: the effects of specific treatment on the growth and development of the children. Lancet 1982; 1: 647-649
25 Chioncel O, Lainscak M, Seferovic PM. et al. Epidemiology and one-year outcomes in patients with chronic heart failure and preserved, mid-range and reduced ejection fraction: an analysis of the ESC Heart Failure Long-Term Registry. Eur J Heart Fail 2017; 19: 1574-1585
26 McDonagh TA, Metra M, Adamo M. et al. 2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure. Eur Heart J 2021; 42: 3599-3726
27 Kasiakogias A, Rosei EA, Camafort M. et al. Hypertension and heart failure with preserved ejection fraction: position paper by the European Society of Hypertension. J Hypertens 2021; 39: 1522-1545
28 Pitt B, Pfeffer MA, Assmann SF. et al. Spironolactone for heart failure with preserved ejection fraction. N Engl J Med 2014; 370: 1383-1392
29 Anker SD, Butler J, Filippatos G. et al. Empagliflozin in Heart Failure with a Preserved Ejection Fraction. N Engl J Med 2021; 385: 1451-1461
30 Tucker KL, Sheppard JP, Stevens R. et al. Self-monitoring of blood pressure in hypertension: A systematic review and individual patient data meta-analysis. PLoS Med 2017; 14: e1002389
31 Persell SD, Peprah YA, Lipiszko D. et al. Effect of Home Blood Pressure Monitoring via a Smartphone Hypertension Coaching Application or Tracking Application on Adults With Uncontrolled Hypertension: A Randomized Clinical Trial. JAMA Netw Open 2020; 3: e200255
32 Kario K, Nomura A, Harada N. et al. Efficacy of a digital therapeutics system in the management of essential hypertension: the HERB-DH1 pivotal trial. Eur Heart J 2021; 42: 4111-4122
33 Beger C, Haller H, Limbourg FP. Telemonitoring and eHealth for arterial hypertension: Status quo and perspectives. Internist 2021; 62: 263-268